Certificate PL-26-00288 · S4 Andarine 25 mg Capsules (60 ct) · lot PL-2610-175 · branded for Epic Wholesalers LLC -dba-Epic Peptides Lab
VerifyCertificate page
Epic Wholesalers LLC -dba-Epic Peptides Lab
Epic Wholesalers LLC -dba-Epic Peptides Lab
Certificate of Analysis · Lot release
www.epicpeptideslab.com
Certificate no.
PL-26-00288
Verification key
HBMER6MR
Scan or enter both at
prymalab.net/testing/verify

Certificate of Analysis · Lot release · Issued for Epic Wholesalers LLC -dba-Epic Peptides Lab

S4 Andarine 25 mg Capsules (60 ct)

Lot PL-2610-175 · Capsules · Label claim 25 mg per capsule
Tested in-house by PrymaLab
In-house analytical result,
not an independent third-party test
Lot / batch number
PL-2610-175
Date made
2026-10-06
Date of analysis
2026-10-08
Date issued
2026-10-15
Retest / expiry
2028-10-06
Units in lot / sampled
394 / 2
Storage
—
Certificate type
Lot COA, 2 pages
Compound
S4
CAS number
401900-40-1
Molecular formula
C19H18F3N3O6
Theoretical mass (avg.)
441.36 Da
Structure
Purity · RP-HPLC, area %
99.73%
Specification ≥ 99.0% • main peak at 10.91 min
Identity · Observed Mass
441.32 Da
Theoretical 441.36 Da • −0.04 Da (91 ppm)
Overall conclusion
PASS
Meets every specification for the tests performed
TestMethodSpecificationResultConclusion
Identity (mass)LC-MS, ESI positiveTheoretical ± 1.0 Da441.32 DaPASS
PurityRP-HPLC, UV 254–306 nm, area%≥ 99.0%99.73%PASS
Largest impurityRP-HPLC, area%≤ 1.0%0.12% (RT 9.80)PASS
Capsule contentContent vs label claim22.5–27.5 mg/cap24.82 mg/capPASS
Bacterial endotoxinLAL, kinetic——N/A
Aerobic count (TAMC)USP <61>< 10 CFU/g< 10 CFU/gPASS
Yeast & mold (TYMC)USP <61>< 10 CFU/g< 10 CFU/gPASS
E. coliUSP <62>AbsentAbsentPASS

1HPLC chromatogram

Data file: PL-2610-175-HPLC.raw · Column C18, 150 × 4.6 mm · UV 254–306 nm
0.01%0.1%1%10%100%891011121314Retention time (min) · stick height = area % (log scale)99.73% · 10.91 min0.12% †0.03% †0.12% †
Peak plot drawn from the integrated peak table (area %, log scale); it is not the instrument trace, which is retained in PL-2610-175-HPLC.raw. † Nominal reference retention time for the assigned impurity; the main-peak RT is observed in this lot.
Epic Wholesalers LLC -dba-Epic Peptides Lab
Epic Wholesalers LLC -dba-Epic Peptides Lab
Certificate of Analysis · continued
S4 Andarine 25 mg Capsules (60 ct) · Lot PL-2610-175 · Certificate PL-26-00288
Lot PL-2610-175
Method, peak table and approval

2HPLC method · PL-2610-175-HPLC.raw

Instrument
Waters Alliance e2695
Data System
Empower 3
Detector
UV absorbance
Detection Wavelength
254–306 nm
Column
C18, 150 × 4.6 mm, 3.5 µm
Mobile Phase A
0.1% TFA in water
Mobile Phase B
0.1% TFA in MeCN
Gradient
5–95% B over 25 min (linear)
Flow Rate
1.0 mL/min
Column Temperature
40 °C
Injection Volume
10 µL

3Gradient program

Time (min)% A% B
0.0955
25.0595

4Peak table

PeakRT (min)AreaArea %
19.80 †—0.12
210.91—99.73
311.90 †—0.03
412.50 †—0.12
Total—100.00
Peaks: 1 unidentified impurity; 2 main peak (S4); 3 unidentified impurity; 4 unidentified impurity · Area % from the integrated peak table (absolute areas are not part of the lot-release export) · † nominal reference RT for the assigned impurity · Purity = main peak area ÷ total integrated area × 100, to two decimals; main peak shaded.

5Identity by mass spectrometry

Instrument
Waters SQD
Ionization / Mode
ESI, positive
Reference m/z (ion)
442.37 [M+H]+
Deconvoluted Mass
441.32 Da
Theoretical Mass
441.36 Da
Difference
−0.04 Da (91 ppm)
Data File
PL-2610-175-MS.d
Acceptance
Within ± 1.0 Da

6Additional tests

TestPerformed byDateReport / file
Content vs label claimPrymaLab Analytical2026-10-08—
Microbial limits (USP <61>/<62>)PrymaLab Analytical2026-10-14—
A test with no row here was not performed on this lot. Outside-laboratory reports, when used, are attached and named below.

7Review and approval

D. Reynolds
Analyst · performed the testing
Date: 2026-10-15
S. Calloway
Reviewer · checked against raw data
Date: 2026-10-15
M. Phelps
Lab Director · approved for release
Date: 2026-10-15